BSE filing, NSE: DEVX. Summary written from the filing by ALFA Finder's alert engine.
Dev Accelerator Ltd: key numbers
- Share price
- ₹40.02
- Market cap
- ₹378.7 Cr
- Revenue (annual)
- ₹225.9 Cr
- Net profit (annual)
- ₹8.80 Cr
- P/E (TTM)
- 37.3×Sector 34.0×
- Promoter holding
- 35.09%+0.00% QoQ
- FII holding
- 1.46%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dev Accelerator Ltd
All →Dev Accelerator Debt & Borrowing: ₹1 Cr
Dev Accelerator paid Rs.1.00 Crore interest on its Rs.100 Crore NCDs on October 27, 2026. The payment was made ahead of the October 31 due date.
- Value
- ₹1.00 Cr
Dev Accelerator Board Meeting Date
Dev Accelerator Ltd scheduled its board meeting for November 3, 2026, to consider Q1 results and NCD issuance. No specific amounts or decisions have been finalized.
Dev Accelerator Debt & Borrowing: ₹0.97 Cr
Dev Accelerator Ltd paid Rs.0.97 Crore as interest on its non-convertible debentures, with the payment executed on September 25, 2026.
- Value
- ₹0.97 Cr
Dev Accelerator Annual General Meeting
Dev Accelerator Limited concluded its 6th Annual General Meeting on September 25, 2026. Shareholders approved all proposed resolutions, including financial statements and various ESOP plan modifications.
Dev Accelerator Share Pledge
Dev Accelerator promoters pledged their equity shares to secure a Rs.100 Crore NCD issue. The revised Reg 31 disclosure details the encumbrance favouring the Debenture Trustee.
- Value
- ₹100.0 Cr
Dev Accelerator Other Announcement
Dev Accelerator Limited notified security holders regarding the availability of the Annual Report for FY 2025-26, fulfilling regulatory compliance requirements.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.